{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:39:45Z","timestamp":1767206385378,"version":"build-2238731810"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202501ZYTS814"],"award-info":[{"award-number":["YDZJ202501ZYTS814"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment for different types of cancers, providing significant clinical benefits. However, these therapies are associated with various immune-related adverse events (irAEs), including hepatic manifestations such as hepatitis, sinusoidal obstruction syndrome (SOS), and nodular regenerative hyperplasia. Among these, regenerative hepatic pseudotumors (RHPs) are exceptionally rare and poorly described in literature. Here, we report the case of a 66-year-old man with metastatic non-small-cell lung cancer (NSCLC) who developed a hepatic pseudotumor during routine imaging following treatment with the anti-programmed cell death 1 (PD-1) therapy, tislelizumab. Despite the presence of a hepatic lesion on imaging, the patient exhibited no clinical symptoms or biochemical evidence of severe immune-mediated hepatitis. Following cessation of anti-PD-1 therapy and initiation of systemic steroid therapy, the hepatic pseudotumors stabilized without further growth. The findings suggest that ICI therapy may be associated with the development of regenerative hepatic pseudotumor (RHP). Given the nonspecific and potentially misleading imaging features of RHP, biopsy is essential for accurate diagnosis and differentiation from malignant lesions such as hepatic metastases. Early histological evaluation through biopsy can prevent unnecessary interventions and guide appropriate management in patients presenting with liver lesions during or after ICI therapy. This case suggests a possible association between the development of RHP and tislelizumab treatment. The effect of ICI-induced hepatic pseudotumors on NSCLC progression is unclear and requires further investigation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1565065","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:13:05Z","timestamp":1748563985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenrui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v119.9","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.esmoop.2024.103728","article-title":"Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)","volume":"9","author":"Lu","year":"2024","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396752","article-title":"Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system","volume":"15","author":"Liang","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1053370","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00822-0","article-title":"Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial","volume":"5","author":"Li","year":"2024","journal-title":"Nat Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","article-title":"Gastrointestinal and hepatic complications of immune checkpoint inhibitors","volume":"19","author":"Cramer","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-012-9469-1","article-title":"The histological growth pattern of colorectal cancer liver metastases has prognostic value","volume":"29","author":"Van den Eynden","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3217","article-title":"Characteristics of common solid liver lesions and recommendations for diagnostic workup","volume":"15","author":"Assy","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B24","article-title":"Inflammatory pseudotumor of the liver: a rare but distinct tumor-like lesion","volume":"8","author":"Balabaud","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver\u2013from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat\u00a0Rev Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology","volume":"13","author":"Hercun","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune-checkpoint inhibitors: a systematic review and meta-analysis","author":"Valenza","year":"2025","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102731","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1200124","article-title":"Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer","volume":"14","author":"Xin","year":"2023","journal-title":"Front Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226993","article-title":"Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis\/cystitis and review of the literature","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619147","article-title":"Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148425","article-title":"Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma","volume":"14","author":"Gu","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756583","article-title":"Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: A case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12890-024-03140-4","article-title":"Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037562","article-title":"Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature","volume":"103","author":"Deng","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1190491","article-title":"Severe thyrotoxicosis induced by tislelizumab: a case report and literature review","volume":"13","author":"Huo","year":"2023","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S330354","article-title":"Pemphigus herpetiformis-type drug reaction caused by programmed cell death protein-1 inhibitor treatment","volume":"14","author":"Zhang","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.v21.10","article-title":"Toxic epidermal necrolysis post apalutamide with preceding tislelizumab administration in a patient with two cancers","volume":"21","author":"Wu","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13214","article-title":"Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer","volume":"61","author":"Kerkemeyer","year":"2020","journal-title":"Australas J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.899971","article-title":"Imaging mass cytometry analysis of immune checkpoint inhibitor-related pneumonitis: A case report","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13401","article-title":"Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis","volume":"11","author":"Ni","year":"2020","journal-title":"Thorac Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1654196","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1565065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:22:14Z","timestamp":1752657734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1565065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2025.1565065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1565065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1565065"}}